Fate Therapeutics, Inc. (FATE)
$1.94-3.00%Close
SELLCRISIS · day 6
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $226M
- Beta
- 2.53
- P/E (TTM)
- -1.85
- Short % float
- 10.56%
- Days to cover
- 5.3
- SI change
- +14.6%
- 1W
- -9.77%
- 1M
- -17.45%
- vs SPY 1W
- -8.79%
- vs SPY 1M
- -19.31%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 1
- GROWTH
- 0
- GARP
- 2
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-39.0%
REV YoY-
ROE-65.1%
EPS YoY-
ROA-48.4%
GROSS-343
OP-2058
NET-1941
[VALUATION]
P/E TTM-1.85
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B1.52
P/FCF-
EV/EBITDA-2.35
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E49.32
ALTMAN Z-
CURR RATIO4.85
ND/EBITDA-
BETA2.53
Company news
FAQ
- What is LOPJLB’s current signal on FATE?
- LOPJLB’s latest quantitative signal on Fate Therapeutics, Inc. (FATE) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is FATE in?
- Fate Therapeutics, Inc. (FATE) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does Fate Therapeutics, Inc. (FATE) do?
- Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute…